Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon Biologics will offer one of the broadest oncology biosimilar portfolios in the industry, addressing some of the world’s highest-revenue biologics that are expected to lose exclusivity over the next five years.
The company’s oncology portfolio represents a market opportunity exceeding $75 billion, accounting for nearly 35% of the global oncology pharmaceutical market. Biocon Limited has also announced plans to integrate Biocon Biologics as a wholly owned subsidiary, which is expected to simplify the corporate structure, enhance global commercial leverage, and strengthen Biocon’s leadership across diabetes, oncology, and immunology.
The integration, which is targeted to be completed by March 31, 2026, subject to regulatory approvals, will enable Biocon to offer biosimilar insulins alongside complex peptide generics, addressing the full continuum of diabetes care. Biocon Biologics’ CEO and Managing Director, Shreehas Tambe, commented that the integration will significantly enhance the company’s ability to deliver high-quality, affordable medicines at scale.
Biocon Biologics is a fully integrated global biosimilars company that serves over 6.3 million patients across 120 countries, providing high-quality biosimilars at affordable costs. The company has commercialized 10 biosimilars to date and has a pipeline of over 20 biosimilar assets spanning various therapeutic areas. Biocon Biologics is committed to advancing environmental, social, and governance priorities aligned with the United Nations Sustainable Development Goals.
The company’s expansion into the oncology market is expected to improve access to affordable cancer treatments worldwide. Biosimilars have been shown to be effective in reducing the cost of biologic treatments, making them more accessible to patients who may not have been able to afford them otherwise. With its expanded portfolio, Biocon Biologics is well-positioned to play a significant role in the global oncology market. The company’s commitment to delivering high-quality, affordable medicines is expected to have a positive impact on patients and healthcare systems worldwide.